{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T15:13:39Z","timestamp":1760800419772,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10072-021-05058-9","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T19:03:01Z","timestamp":1611082981000},"page":"15-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Two-year follow-up during fingolimod treatment in a pediatric multiple sclerosis patient still active on first-line treatment"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3903","authenticated-orcid":false,"given":"Paolo","family":"Immovilli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Rota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Guidetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"3","key":"5058_CR1","first-page":"793","volume":"25","author":"T Chitnis","year":"2019","unstructured":"Chitnis T (2019) Pediatric central nervous system demyelinating diseases. Continuum (Minneap Minn) 25(3):793\u2013814","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"5058_CR2","doi-asserted-by":"publisher","first-page":"e20160120","DOI":"10.1542\/peds.2016-0120","volume":"138","author":"AL Belman","year":"2016","unstructured":"Belman AL, Krupp LB, Olsen CS, Rose JW, Aaen G, Benson L et al (2016) Characteristics of children and adolescents with multiple sclerosis. Pediatrics 138(1):e20160120","journal-title":"Pediatrics"},{"issue":"1","key":"5058_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/1352458512445944","volume":"19","author":"M Absoud","year":"2013","unstructured":"Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R et al (2013) Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 19(1):76\u201386","journal-title":"Mult Scler"},{"issue":"3","key":"5058_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1212\/01.wnl.0000339482.84392.bd","volume":"72","author":"B Banwell","year":"2009","unstructured":"Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, Connolly MB, Yager J, Mah JK, Shah N, Sebire G, Meaney B, Dilenge ME, Lortie A, Whiting S, Doja A, Levin S, MacDonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Guimond C, Cooper P, Grand'Maison F, Baird JB, Bhan V, Bar-Or A (2009) Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 72(3):232\u2013239","journal-title":"Neurology."},{"issue":"2","key":"5058_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","volume":"3","author":"LA Benson","year":"2014","unstructured":"Benson LA, Healy BC, Gorman MP, Baruch NF, Gholipour T, Musallam A, Chitnis T (2014) Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord 3(2):186\u2013193","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"5058_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/archneurol.2008.505","volume":"66","author":"MP Gorman","year":"2009","unstructured":"Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T (2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 66(1):54\u201359","journal-title":"Arch Neurol"},{"issue":"24","key":"5058_CR7","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1212\/WNL.0000000000000524","volume":"82","author":"MT Malik","year":"2014","unstructured":"Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T (2014) Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology. 82(24):2173\u20132179","journal-title":"Neurology."},{"issue":"7","key":"5058_CR8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/1352458511431725","volume":"18","author":"AJ Fay","year":"2012","unstructured":"Fay AJ, Mowry EM, Strober J, Waubant E (2012) Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler 18(7):1008\u20131012","journal-title":"Mult Scler"},{"issue":"25","key":"5058_CR9","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa067597","volume":"356","author":"C Renoux","year":"2007","unstructured":"Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 356(25):2603\u20132613","journal-title":"N Engl J Med"},{"issue":"2","key":"5058_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302","journal-title":"Ann Neurol"},{"issue":"2","key":"5058_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","volume":"83","author":"RC Dale","year":"2014","unstructured":"Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan PA, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M (2014) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 83(2):142\u2013150","journal-title":"Neurology."},{"key":"5058_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jns.2016.01.023","volume":"363","author":"LB Krupp","year":"2016","unstructured":"Krupp LB, Pohl D, Ghezzi A, Boyko A, Tenembaum S, Chen L, Aycardi E, Banwell B, REPLAY Study Group (2016) Subcutaneous interferon beta-1a in pediatric patients with multiple sclerosis: regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study. J Neurol Sci 363:33\u201338","journal-title":"J Neurol Sci"},{"issue":"7","key":"5058_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/0883073813488828","volume":"28","author":"SN Tenembaum","year":"2013","unstructured":"Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, Lehr L, Rocak S, Cantogno EV, Moraga MS, Ghezzi A, REPLAY Study Group (2013) Subcutaneous interferon beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol 28(7):849\u2013856","journal-title":"J Child Neurol"},{"key":"5058_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12883-015-0433-y","volume":"15","author":"A Ghezzi","year":"2015","unstructured":"Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM et al (2015) Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol 15:174","journal-title":"BMC Neurol"},{"issue":"8","key":"5058_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1177\/1352458512471878","volume":"19","author":"A Ghezzi","year":"2013","unstructured":"Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M, the Italian MS Study Group (2013) Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler 19(8):1106\u20131112","journal-title":"Mult Scler"},{"issue":"11","key":"5058_CR16","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","volume":"379","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Arnold DL, Banwell B, Bruck W, Ghezzi A, Giovannoni G et al (2018) Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med 379(11):1017\u20131027","journal-title":"N Engl J Med"},{"issue":"6","key":"5058_CR17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76(6):802\u2013812","journal-title":"Ann Neurol"},{"issue":"1","key":"5058_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25737","volume":"88","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G, Belman A, Benson L, Chitnis T, Gorman M, Goyal MS, Harris Y, Krupp L, Lotze T, Mar S, Moodley M, Ness J, Rodriguez M, Rose J, Schreiner T, Tillema JM, Waltz M, Casper TC, Waubant E, the US Network of Pediatric MS Centers (2020) Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol 88(1):42\u201355","journal-title":"Ann Neurol"},{"issue":"11","key":"5058_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"PR Ho","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I (2017) Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 16(11):925\u2013933","journal-title":"Lancet Neurol"},{"issue":"12","key":"5058_CR20","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10072-013-1485-7","volume":"34","author":"M Filippi","year":"2013","unstructured":"Filippi M, Rocca MA, Bastianello S, Comi G, Gallo P, Gallucci M, Ghezzi A, Marrosu MG, Minonzio G, Pantano P, Pozzilli C, Tedeschi G, Trojano M, Falini A, de Stefano N, Neuroimaging and MS Study Groups of the Italian Society of Neurology, Functional Neuroradiology Section of the Italian Association of Neuroradiology (2013) Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurol Sci 34(12):2085\u20132093","journal-title":"Neurol Sci"},{"issue":"2","key":"5058_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72(2):152\u2013158","journal-title":"JAMA Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05058-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:03:21Z","timestamp":1659060201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05058-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":21,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5058"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05058-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"12 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Immovilli has received honoraria as a speaker and advisory board member from TEVA, Merck, Biogen, and Roche. Drs Rota, Morelli, and Guidetti have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the local ethics committee of the Guglielmo da Saliceto Civil Hospital in Piacenza, Italy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to participate was obtained from legal guardians. Informed consent to publish was obtained from legal guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}